213 related articles for article (PubMed ID: 37668079)
1. RAIDS atlas of significant genetic and protein biomarkers in cervical cancer.
Scholl S; Roufai DB; Chérif LL; Kamal M
J Gynecol Oncol; 2023 Sep; 34(5):e74. PubMed ID: 37668079
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Wang J; Chai YL; Wang T; Liu JH; Dai PG; Liu Z
Exp Mol Pathol; 2015 Jun; 98(3):407-10. PubMed ID: 25773678
[TBL] [Abstract][Full Text] [Related]
4. Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.
Scholl SM; Beal J; de Koning L; Girard E; Popovic M; de la Rochefordière A; Lecuru F; Fourchotte V; Ngo C; Floquet A; Berns EM; Kenter G; Gestraud P; von der Leyen H; Lecerf C; Puard V; Roman SR; Latouche A; Kereszt A; Balint B; Rouzier R; Kamal M
EBioMedicine; 2020 Nov; 61():103049. PubMed ID: 33096476
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
[TBL] [Abstract][Full Text] [Related]
6. Cervical Carcinoma: Oncobiology and Biomarkers.
Volkova LV; Pashov AI; Omelchuk NN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830452
[TBL] [Abstract][Full Text] [Related]
7. Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer.
Halle C; Lando M; Svendsrud DH; Clancy T; Holden M; Sundfør K; Kristensen GB; Holm R; Lyng H
Clin Cancer Res; 2011 Aug; 17(16):5501-12. PubMed ID: 21737508
[TBL] [Abstract][Full Text] [Related]
8. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. In regard to Shaverdian et al.
Hintz B
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):633-4. PubMed ID: 24138909
[No Abstract] [Full Text] [Related]
10. Predictive Value of Standardized Intratumoral Metabolic Heterogeneity in Locally Advanced Cervical Cancer Treated With Chemoradiation.
Yang F; Young L; Grigsby P
Int J Gynecol Cancer; 2016 May; 26(4):777-84. PubMed ID: 27101524
[TBL] [Abstract][Full Text] [Related]
11. Effect of GREM 1 gene on chemoradiotherapy sensitivity of cervical squamous carcinoma cells.
Miao H; Song WB; Zhu H; Wang Q; Tian Y
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1072-1080. PubMed ID: 32096207
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
Bai ZL; Wang YY; Zhe H; He JL; Hai P
Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
[TBL] [Abstract][Full Text] [Related]
14. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis.
Choi KH; Yu M; Jeong S; Lee JH
Int J Clin Oncol; 2020 Jul; 25(7):1405-1411. PubMed ID: 32221801
[TBL] [Abstract][Full Text] [Related]
15. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
Wang W; Liu X; Hou X; Lian X; Liu Z; Shen J; Sun S; Yan J; Miao Z; Wang D; Meng Q; Fu J; Zhang F; Qiu J; Hu K
Gynecol Oncol; 2019 Nov; 155(2):224-228. PubMed ID: 31500891
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
Rose PG; Java JJ; Whitney CW; Stehman FB; Lanciano R; Thomas GM
Gynecol Oncol; 2014 Nov; 135(2):208-12. PubMed ID: 25152438
[TBL] [Abstract][Full Text] [Related]
17. Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis.
Tergas AI; Neugut AI; Chen L; Burke WM; Hershman DL; Wright JD
Cancer Invest; 2016; 34(3):137-47. PubMed ID: 26986809
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
19. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer.
Mizunuma M; Yokoyama Y; Futagami M; Aoki M; Takai Y; Mizunuma H
Int J Clin Oncol; 2015 Oct; 20(5):989-96. PubMed ID: 25736530
[TBL] [Abstract][Full Text] [Related]
20. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
